Tumors were usually ductal carcinomas, estrogen- and progesterone-positive, stage I/II, and Grade 2/3, with a 5-month delay on average between initial signs and diagnostic imaging. Treatments followed ...
Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment between 2015 ...
In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...
Investigators retrospectively examined the charts of 12,765 Medicare beneficiaries diagnosed with ERBB2-positive breast cancer between 2010 and 2019. Despite improvements in equity, overall ...
What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...
EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results